Further delineation of EZH2 mechanisms in SCLC cisplatin resistance, by Koyen et al., revealed the non-catalytic and PRC2-independent role of EZH2 in stabilizing DDB2 (Damage Specific DNA Binding Protein 2). This evidence concerns the gene DDB2 and small cell lung carcinoma.